New therapeutic approaches by using microorganism-derived compounds

Area of Science:

• Microbiology
• Pharmacology
• Natural Products Chemistry

Background:

• Natural products have historically been crucial for drug discovery, with microorganisms providing a vast chemical diversity.
• Microorganisms like bacteria and fungi produce numerous antimicrobial agents and other bioactive compounds.
• Despite advances in synthetic chemistry, natural products remain vital for identifying new therapeutic leads.

Purpose of the Study:

• To review the current therapeutic applications of microorganism-derived products (MdPs).
• To explore the future potential of MdPs in various medical fields.
• To discuss clinical trial outcomes for MdPs.

Main Methods:

• Literature review of scientific publications on microorganism-derived products.
• Analysis of existing data on clinical trials involving MdPs.
• Synthesis of information on the discovery and development of drugs from microbial sources.

Main Results:

• Microorganisms have yielded significant drugs, including antibiotics (e.g., penicillin, cephalosporins, tetracyclines) and non-antibiotic therapeutics.
• Notable examples include lovastatin (cholesterol-lowering), ciclosporin (immunosuppressant), and sirolimus (anti-cancer).
• MdPs are crucial in antibacterial therapy and have expanded into immunosuppression, cholesterol management, and oncology.

Conclusions:

• Microorganism-derived products continue to be a cornerstone of modern medicine, offering diverse therapeutic solutions.
• Future research holds promise for discovering novel MdPs with applications beyond current uses.
• Clinical validation and development of MdPs are essential for advancing therapeutic treatments.